LENZ THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.7 USD | -0.13% |
|
-5.02% | 0.00% |
| Apr. 15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
| Apr. 15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 6.73M | Capitalization | 401M |
|---|---|---|---|---|---|
| Net income 2024 * | -52M | Net income 2025 * | -66M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 59.7 x |
| P/E ratio 2024 * |
-5.62
x | P/E ratio 2025 * |
-6.56
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.17% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.13% | ||
| 1 week | -5.02% | ||
| Current month | -1.07% | ||
| 1 month | -1.38% |
1 week
15.09
19.92
1 month
15.0019.92
Current year
15.0024.59
1 year
15.0024.59
3 years
15.0024.59
5 years
15.0024.59
10 years
15.0024.59
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 15.7 | -0.13% | 214,362 |
| 24-05-23 | 15.72 | -14.61% | 436,875 |
| 24-05-22 | 18.41 | -1.23% | 116,069 |
| 24-05-21 | 18.64 | +0.27% | 189,530 |
| 24-05-20 | 18.59 | +13.70% | 130,272 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotes
LENZ Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. Its product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase III CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States.
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
15.7
USD
Average target price
35.6
USD
Spread / Average Target
+126.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 401M | |
| +12.30% | 116B | |
| +12.15% | 106B | |
| -8.14% | 23.89B | |
| -1.69% | 21.58B | |
| -10.60% | 18.96B | |
| -41.25% | 16.96B | |
| -15.33% | 16.33B | |
| +5.80% | 14.14B | |
| +28.03% | 12.02B |
- Stock Market
- Equities
- LENZ Stock
